Is RXST or QDEL more profitable?

RxSight has a net margin of -36.80% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% QuidelOrtho -39.20% 4.88% 1.63%

Does the media prefer RXST or QDEL?

In the previous week, RxSight had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for RxSight and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.73 beat RxSight's score of -0.05 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral QuidelOrtho 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, RXST or CERS?

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $134.48M 1.46 -$38.94M -$1.13 N/A Cerus $206.13M 2.55 -$15.63M -$0.03 N/A

Is RXST or CERS more profitable?

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Cerus -3.06% -10.19% -3.14%

Does the media prefer RXST or CERS?

In the previous week, RxSight had 5 more articles in the media than Cerus. MarketBeat recorded 8 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 0.56 beat RxSight's score of -0.05 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SMTI or RXST more profitable?

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% RxSight -36.80% -17.35% -14.70%

Does the media favor SMTI or RXST?

In the previous week, RxSight had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.91 beat RxSight's score of -0.05 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, RXST or EMBC?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $134.48M 1.46 -$38.94M -$1.13 N/A Embecta $1.08B 0.29 $95.40M $1.48 3.80

Is RXST or EMBC more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.80% -17.35% -14.70% Embecta 8.59% -19.25% 10.82%

Does the media refer more to RXST or EMBC?

In the previous week, RxSight had 3 more articles in the media than Embecta. MarketBeat recorded 8 mentions for RxSight and 5 mentions for Embecta. Embecta's average media sentiment score of 0.34 beat RxSight's score of -0.05 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Embecta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

RxSight (RXST) Competitors

$4.73 -0.12 (-2.47%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$4.68 -0.05 (-1.06%)

As of 09/24/2026 07:30 PM Eastern

Compare

RXST vs. QDEL, CERS, SMTI, EMBC, and OSUR

Should you buy RxSight stock or one of its competitors? RxSight's main competitors and comparable companies include QuidelOrtho (QDEL), Cerus (CERS), Sanara MedTech (SMTI), Embecta (EMBC), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does RxSight compare to QuidelOrtho?

RxSight (NASDAQ:RXST) and QuidelOrtho (NASDAQ:QDEL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

RxSight has higher earnings, but lower revenue than QuidelOrtho. RxSight is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A

RxSight has a net margin of -36.80% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
QuidelOrtho	-39.20%	4.88%	1.63%

78.8% of RxSight shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

RxSight presently has a consensus target price of $8.17, indicating a potential upside of 72.77%. QuidelOrtho has a consensus target price of $13.63, indicating a potential upside of 27.46%. Given RxSight's stronger consensus rating and higher possible upside, equities analysts plainly believe RxSight is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, RxSight had 3 more articles in the media than QuidelOrtho. MarketBeat recorded 8 mentions for RxSight and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.73 beat RxSight's score of -0.05 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
QuidelOrtho	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Summary

RxSight beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does RxSight compare to Cerus?

RxSight (NASDAQ:RXST) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Cerus has a net margin of -3.06% compared to RxSight's net margin of -36.80%. Cerus' return on equity of -10.19% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Cerus	-3.06%	-10.19%	-3.14%

Cerus has higher revenue and earnings than RxSight. Cerus is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A
Cerus	$206.13M	2.55	-$15.63M	-$0.03	N/A

RxSight has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Cerus has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

In the previous week, RxSight had 5 more articles in the media than Cerus. MarketBeat recorded 8 mentions for RxSight and 3 mentions for Cerus. Cerus' average media sentiment score of 0.56 beat RxSight's score of -0.05 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RxSight currently has a consensus price target of $8.17, indicating a potential upside of 72.77%. Cerus has a consensus price target of $5.25, indicating a potential upside of 101.15%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

78.8% of RxSight shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 5.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cerus beats RxSight on 12 of the 16 factors compared between the two stocks.

How does RxSight compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

Sanara MedTech has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, RxSight has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Sanara MedTech presently has a consensus price target of $35.00, indicating a potential downside of 0.28%. RxSight has a consensus price target of $8.17, indicating a potential upside of 72.77%. Given RxSight's stronger consensus rating and higher possible upside, analysts clearly believe RxSight is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Sanara MedTech has a net margin of -29.15% compared to RxSight's net margin of -36.80%. Sanara MedTech's return on equity of 29.72% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
RxSight	-36.80%	-17.35%	-14.70%

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Comparatively, 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sanara MedTech has higher earnings, but lower revenue than RxSight. Sanara MedTech is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A

In the previous week, RxSight had 6 more articles in the media than Sanara MedTech. MarketBeat recorded 8 mentions for RxSight and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.91 beat RxSight's score of -0.05 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight beats Sanara MedTech on 8 of the 15 factors compared between the two stocks.

How does RxSight compare to Embecta?

RxSight (NASDAQ:RXST) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, RxSight had 3 more articles in the media than Embecta. MarketBeat recorded 8 mentions for RxSight and 5 mentions for Embecta. Embecta's average media sentiment score of 0.34 beat RxSight's score of -0.05 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.8% of RxSight shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 10.1% of RxSight shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

RxSight has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Embecta has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

RxSight currently has a consensus target price of $8.17, suggesting a potential upside of 72.77%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 95.73%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.80%	-17.35%	-14.70%
Embecta	8.59%	-19.25%	10.82%

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A
Embecta	$1.08B	0.29	$95.40M	$1.48	3.80

Summary

Embecta beats RxSight on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to OraSure Technologies?

OraSure Technologies (NASDAQ:OSUR) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

OraSure Technologies presently has a consensus target price of $3.00, indicating a potential downside of 23.66%. RxSight has a consensus target price of $8.17, indicating a potential upside of 72.77%. Given RxSight's stronger consensus rating and higher probable upside, analysts plainly believe RxSight is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

RxSight has a net margin of -36.80% compared to OraSure Technologies' net margin of -43.70%. RxSight's return on equity of -17.35% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OraSure Technologies	-43.70%	-19.09%	-16.26%
RxSight	-36.80%	-17.35%	-14.70%

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by insiders. Comparatively, 10.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, RxSight had 7 more articles in the media than OraSure Technologies. MarketBeat recorded 8 mentions for RxSight and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.25 beat RxSight's score of -0.05 indicating that OraSure Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
OraSure Technologies	Positive
RxSight	Neutral

RxSight has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OraSure Technologies	$115.02M	2.36	-$68.73M	-$0.69	N/A
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A

OraSure Technologies has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, RxSight has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Summary

RxSight beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$205.05M	$5.63B	$7.32B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-4.19	25.36	274.40	25.76
Price / Sales	1.46	71.00	688.47	106.32
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	0.71	5.74	10.52	6.34
Net Income	-$38.94M	$151.55M	$3.49B	$360.00M
7 Day Performance	-9.04%	-0.45%	-0.94%	-0.16%
1 Month Performance	-26.09%	-4.20%	-4.24%	-4.07%
1 Year Performance	-47.79%	7.41%	16.39%	5.97%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	2.4284 of 5 stars	$4.73 -2.5%	$8.17 +72.8%	-48.5%	$205.05M	$134.48M	N/A	461	Analyst Forecast
QDEL QuidelOrtho	3.4371 of 5 stars	$11.07 -0.4%	$13.63 +23.1%	-59.9%	$761.53M	$2.67B	N/A	6,500	News Coverage
CERS Cerus	1.7689 of 5 stars	$2.52 -1.4%	$5.25 +108.7%	+69.5%	$506.84M	$221.55M	N/A	345	News Coverage Positive News
SMTI Sanara MedTech	0.6146 of 5 stars	$35.13 +0.4%	$35.00 -0.4%	+7.8%	$322.82M	$103.12M	N/A	108	News Coverage
EMBC Embecta	3.9254 of 5 stars	$5.11 -2.6%	$11.00 +115.5%	-61.5%	$289.25M	$1.02B	3.45	1,850

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors